Vigil Neuroscience, Inc. (VIGL)


+0.61 (+8.34%)
Symbol VIGL
Price $7.92
Beta 0.000
Volume Avg. 0.06M
Market Cap 223.885M
Shares () -
52 Week Range 2.18-18.27
1y Target Est -
DCF Unlevered VIGL DCF ->
DCF Levered VIGL LDCF ->
ROE -24.79% Sell
ROA -9.71% Neutral
Operating Margin -
Debt / Equity 4.85% Neutral
P/E -
P/B 1.48 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest VIGL news

NASDAQ Global Select

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.